The monosodium glutamate symptom complex: Assessment in a double-blind, placebo-controlled, randomized study

被引:85
|
作者
Yang, WH
Drouin, MA
Herbert, M
Mao, Y
Karsh, J
机构
[1] UNIV OTTAWA, DEPT MED, OTTAWA, ON, CANADA
[2] HLTH CANADA, LAB CTR DIS CONTROL, OTTAWA, ON K1A 0L2, CANADA
[3] HLTH CANADA, BUR CHRON DIS EPIDEMIOL, OTTAWA, ON K1A 0L2, CANADA
关键词
monosodium glutamate; monosodium glutamate symptom complex; randomized double-blind challenge;
D O I
10.1016/S0091-6749(97)80008-5
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Considerable debate swirls about the validity of symptoms described by many people after ingestion of monosodium glutamate (MSG), and the question has remained unresolved largely because of a paucity of well-designed challenge studies. Methods: We conducted oral challenge studies in self-identified MSG-sensitive subjects to determine whether they had a statistically significant difference in the incidence of their specific symptoms after ingestion of MSG compared with placebo. First, 5 gm MSG or placebo was administered in random sequence in a double-blind fashion. Subjects who reacted only to a single test agent then underwent rechallenge in random sequence in a double-blind fashion with placebo and 1.25, 2.5, and 5 gm MSG. A positive response to challenge was defined as the reproduction of greater than or equal to 2 of the specific symptoms in a subject ascertained on prechallenge interview. Results: Sixty-one subjects entered the study. On initial challenge, 18 (29.5%) responded to neither MSG nor placebo, 6 (9.8%) to both, 15 (24.6%) to placebo, and 22 (36.1%) to MSG (p = 0.324). Total and average severity of symptoms after ingestion of MSG (374 and 80) were greater than respective values after placebo ingestion (232 and 56; p = 0.026 and 0.018, respectively). Rechallenge revealed an apparent threshold dose for reactivity of 2.5 gm MSG. Headache (p < 0.023), muscle tightness (p < 0.004), numbness/tingling (p < 0.007), general weakness (p < 0.040), and Bushing (p < 0.016) occurred more frequently after MSG than placebo ingestion. Conclusions: Oral challenge with MSG reproduced symptoms in alleged sensitive persons. The mechanism of the reaction remains unknown, but symptom characteristics do not support an IgE-mediated mechanism. According to Food and Drug Administration recommendations, the symptoms, originally called the Chinese restaurant syndrome, are better referred to as the MSG symptom complex.
引用
收藏
页码:757 / 762
页数:6
相关论文
共 50 条
  • [41] PAROXETINE TREATMENT OF PREMATURE EJACULATION - A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY
    WALDINGER, MD
    HENGEVELD, MW
    ZWINDERMAN, AH
    AMERICAN JOURNAL OF PSYCHIATRY, 1994, 151 (09): : 1377 - 1379
  • [42] A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy
    Fuentes, VL
    Corcoran, B
    French, A
    Schober, KE
    Kellemann, R
    Justus, C
    PRAKTISCHE TIERARZT, 2003, 84 (09): : 658 - +
  • [43] Treatment of rheumatoid arthritis with ornidazole: a randomized, double-blind, placebo-controlled study
    Ogrendik, Mesut
    RHEUMATOLOGY INTERNATIONAL, 2006, 26 (12) : 1132 - 1137
  • [44] A randomized, double-blind, placebo-controlled study of methylphenidate in patients with organic amnesia
    Tiberti, C
    Sabe, L
    Jason, L
    Leiguarda, R
    Starkstein, S
    EUROPEAN JOURNAL OF NEUROLOGY, 1998, 5 (03) : 297 - 299
  • [45] The effect of ubiquinone in diabetic polyneuropathy: A randomized double-blind placebo-controlled study
    Hernandez-Ojeda, Jaime
    Cardona-Munoz, Ernesto G.
    Roman-Pintos, Luis M.
    Troyo-Sanroman, Rogelio
    Ortiz-Lazareno, Pablo C.
    Cardenas-Meza, Mario A.
    Pascoe-Gonzalez, Sara
    Miranda-Diaz, Alejandra G.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2012, 26 (04) : 352 - 358
  • [46] Givinostat for Becker muscular dystrophy: A randomized, placebo-controlled, double-blind study
    Comi, Giacomo P.
    Niks, Erik H.
    Vandenborne, Krista
    Cinnante, Claudia M.
    Kan, Hermien E.
    Willcocks, Rebecca J.
    Velardo, Daniele
    Magri, Francesca
    Ripolone, Michela
    van Benthem, Jules J.
    van de Velde, Nienke M.
    Nava, Simone
    Ambrosoli, Laura
    Cazzaniga, Sara
    Bettica, Paolo U.
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [47] Octreotide in hepatorenal syndrome: A randomized, double-blind, placebo-controlled, crossover study
    Pomier-Layrargues, G
    Paquin, SC
    Hassoun, Z
    Lafortune, M
    Tran, A
    HEPATOLOGY, 2003, 38 (01) : 238 - 243
  • [48] Corticosteroids in the treatment of tuberculous pleurisy - A double-blind, placebo-controlled, randomized study
    Wyser, C
    Walzl, G
    Smedema, JP
    Swart, F
    vanSchalkwyk, EM
    vandeWal, BW
    CHEST, 1996, 110 (02) : 333 - 338
  • [49] Inorganic Nitrate in Angina Study: A Randomized Double-Blind Placebo-Controlled Trial
    Schwarz, Konstantin
    Singh, Satnam
    Parasuraman, Satish K.
    Rudd, Amelia
    Shepstone, Lee
    Feelisch, Martin
    Minnion, Magdalena
    Ahmad, Shakil
    Madhani, Melanie
    Horowitz, John
    Dawson, Dana K.
    Frenneaux, Michael P.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (09):
  • [50] Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome
    Wagner, ML
    Walters, AS
    Coleman, RG
    Hening, WA
    Grasing, K
    Chokroverty, S
    SLEEP, 1996, 19 (01): : 52 - 58